PUNT OF THE WEEK: Veterinary and pet pharma firm CVS

PUNT OF THE WEEK: Veterinary and pet pharma firm CVS is thriving during the pandemic By Daily Mail City & Finance Reporter Published: 22:00 BST, 23 October 2020 | Updated: 22:25 BST, 23 October 2020 WHAT IS IT? Rather than investing in stocks, it buys debt and other instruments issued by banks to meet their regulatory … Read more

MARKET REPORT: Pharma giants boosted as Covid-19 vaccine hopes grow

MARKET REPORT: Pharma giants Astrazeneca and Glaxosmithkline boosted as Covid-19 vaccine hopes grow By Francesca Washtell For The Daily Mail Published: 21:50 BST, 7 September 2020 | Updated: 22:15 BST, 7 September 2020 Markets started the week on the front foot as pharmaceuticals firms large and small made strides in the battle to beat Covid-19. … Read more

MARKET REPORT: Investors back British pharma to beat Covid

MARKET REPORT: In the battle to beat coronavirus, London-listed companies both large and small punch well above their weight By Francesca Washtell For The Daily Mail Published: 22:19 BST, 27 August 2020 | Updated: 22:21 BST, 27 August 2020 In the battle to beat Covid-19, London-listed companies both large and small have punched well above … Read more

MARKET REPORT: Fight to defeat Covid-19 boosts pharma minnow  Verona

Verona Pharma became the latest biotechnology minnow to wow London investors with its work to help combat Covid-19. The AIM-listed group has been given permission by US authorities to test an inhaler containing its drug ensifentrine on hospitalised coronavirus patients in Alabama. It believes the chronic obstructive pulmonary disease (COPD) treatment could help reduce inflammation … Read more

Big Pharma spent nearly $250 million to lobby lawmakers amid coronavirus pandemic

Big Pharma spent nearly $250 MILLION to sway lawmakers amid the pandemic: Firms making coronavirus drugs and vaccines like Biogen and Novartis accounted for 25% of all lobbying spending in the first quarter of 2020 Researchers found the health sector spent $250million lobbying lawmakers from January 1 to March 31 of 2020 This accounts of … Read more

Jonathan Sackler, co-owner of Purdue Pharma, dies of cancer aged 65

Jonathan Sackler, co-owner of Purdue Pharma, dead of cancer at 65 Jonathan Sackler, one of the owners of Purdue Pharma, has died aged 65  His death was revealed in a court filing which lists the cause as cancer  Purdue, which makes painkiller OxyContin, is at the center of US opioid crisis Company is facing thousands … Read more

French pharma boss who could save the UK from Covid-19

Pascal Soriot is on a mission. Not satisfied that in the midst of the coronavirus pandemic AstraZeneca has become Britain’s most valuable company, he believes that his scientists – together with those of Oxford University – are well on the way to producing the first proven vaccine against SARS-CoV-2, the virus behind the pandemic. Not … Read more

ALEX BRUMMER: Analysts in overdrive on pharma merger talk

ALEX BRUMMER: Pharmaceutical analysts in overdrive at prospect of mega-merger between Astrazeneca and Gilead By Alex Brummer for the Daily Mail Published: 22:00 BST, 8 June 2020 | Updated: 22:00 BST, 8 June 2020 Nothing gets the blood running in the investment community like the prospect of a mega-merger. So the possibility of Astrazeneca and … Read more

Coronavirus crisis shines a light on small-cap pharma groups like Scancell

As global efforts to tackle the pandemic intensify, so the spotlight has finally shifted to focus on the potential of small pharma players during the week beginning 27th April. According to Ivan Sedgwick, a director at corporate finance firm LGB & Co, the poor share price performance of major healthcare names has demoralised investors, forcing … Read more

ALEX BRUMMER: UK Big pharma in the fight against covid-19

Britain’s world class big pharma companies were always going to be a huge asset in the fight against Covid-19 and in finding solutions, not just to this pandemic, but to future similar events. We have now been offered insights into their thinking. Glaxosmithkline, where Emma Walmsley’s first years as chief executive were marked by some … Read more